EGFR and non-small cell lung carcinoma: Furthermore, Teliso-V has shown potential in NSCLC treatment when combined with other modalities such as immune checkpoint inhibitors, i.e., anti-PD-1, chemotherapy, or EGFR-TKIs (43).